137 related articles for article (PubMed ID: 32749403)
1. Conformational selection vs. induced fit: insights into the binding mechanisms of p38α MAP Kinase inhibitors.
Roser P; Weisner J; Stehle J; Rauh D; Drescher M
Chem Commun (Camb); 2020 Aug; 56(62):8818-8821. PubMed ID: 32749403
[TBL] [Abstract][Full Text] [Related]
2. Direct monitoring of the conformational equilibria of the activation loop in the mitogen-activated protein kinase p38α.
Roser P; Weisner J; Simard JR; Rauh D; Drescher M
Chem Commun (Camb); 2018 Oct; 54(85):12057-12060. PubMed ID: 30295691
[TBL] [Abstract][Full Text] [Related]
3. p38α MAPK and Type I Inhibitors: Binding Site Analysis and Use of Target Ensembles in Virtual Screening.
Astolfi A; Iraci N; Sabatini S; Barreca ML; Cecchetti V
Molecules; 2015 Aug; 20(9):15842-61. PubMed ID: 26334265
[TBL] [Abstract][Full Text] [Related]
4. Insights from free-energy calculations: protein conformational equilibrium, driving forces, and ligand-binding modes.
Huang YM; Chen W; Potter MJ; Chang CE
Biophys J; 2012 Jul; 103(2):342-51. PubMed ID: 22853912
[TBL] [Abstract][Full Text] [Related]
5. Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases.
Muth F; Günther M; Bauer SM; Döring E; Fischer S; Maier J; Drückes P; Köppler J; Trappe J; Rothbauer U; Koch P; Laufer SA
J Med Chem; 2015 Jan; 58(1):443-56. PubMed ID: 25475894
[TBL] [Abstract][Full Text] [Related]
6. Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.
Cumming JG; Debreczeni JÉ; Edfeldt F; Evertsson E; Harrison M; Holdgate GA; James MJ; Lamont SG; Oldham K; Sullivan JE; Wells SL
J Med Chem; 2015 Jan; 58(1):278-93. PubMed ID: 25255283
[TBL] [Abstract][Full Text] [Related]
7. Human p38α mitogen-activated protein kinase in the Asp168-Phe169-Gly170-in (DFG-in) state can bind allosteric inhibitor Doramapimod.
Suplatov D; Kopylov K; Sharapova Y; Švedas V
J Biomol Struct Dyn; 2019 May; 37(8):2049-2060. PubMed ID: 29749295
[TBL] [Abstract][Full Text] [Related]
8. Identification of a Novel Inhibitory Allosteric Site in p38α.
Gomez-Gutierrez P; Campos PM; Vega M; Perez JJ
PLoS One; 2016; 11(11):e0167379. PubMed ID: 27898710
[TBL] [Abstract][Full Text] [Related]
9. The identification of novel p38α isoform selective kinase inhibitors having an unprecedented p38α binding mode.
Wrobleski ST; Lin S; Dhar TG; Dyckman AJ; Li T; Pitt S; Zhang R; Fan Y; Doweyko AM; Tokarski JS; Kish KF; Kiefer SE; Sack JS; Newitt JA; Witmer MR; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2013 Jul; 23(14):4120-6. PubMed ID: 23746475
[TBL] [Abstract][Full Text] [Related]
10. Rapid identification of ligand-binding sites by using an assignment-free NMR approach.
Kodama Y; Takeuchi K; Shimba N; Ishikawa K; Suzuki E; Shimada I; Takahashi H
J Med Chem; 2013 Nov; 56(22):9342-50. PubMed ID: 24171460
[TBL] [Abstract][Full Text] [Related]
11. A temperature-dependent conformational shift in p38α MAPK substrate-binding region associated with changes in substrate phosphorylation profile.
Deredge D; Wintrode PL; Tulapurkar ME; Nagarsekar A; Zhang Y; Weber DJ; Shapiro P; Hasday JD
J Biol Chem; 2019 Aug; 294(34):12624-12637. PubMed ID: 31213525
[TBL] [Abstract][Full Text] [Related]
12. Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids.
Goettert M; Schattel V; Koch P; Merfort I; Laufer S
Chembiochem; 2010 Dec; 11(18):2579-88. PubMed ID: 21108268
[TBL] [Abstract][Full Text] [Related]
13. Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38α MAP kinase.
Yang Y; Shen Y; Liu H; Yao X
J Chem Inf Model; 2011 Dec; 51(12):3235-46. PubMed ID: 22097958
[TBL] [Abstract][Full Text] [Related]
14. Lipid molecules induce p38α activation via a novel molecular switch.
Tzarum N; Eisenberg-Domovich Y; Gills JJ; Dennis PA; Livnah O
J Mol Biol; 2012 Dec; 424(5):339-53. PubMed ID: 23079240
[TBL] [Abstract][Full Text] [Related]
15. Modeling the binding affinity of p38α MAP kinase inhibitors by partial least squares regression.
Basant N; Durante C; Cocchi M; Menziani MC
Chem Biol Drug Des; 2012 Sep; 80(3):455-70. PubMed ID: 22642504
[TBL] [Abstract][Full Text] [Related]
16. A Comprehensive Structural Overview of p38α MAPK in Complex with Type I Inhibitors.
Astolfi A; Iraci N; Manfroni G; Barreca ML; Cecchetti V
ChemMedChem; 2015 Jun; 10(6):957-69. PubMed ID: 26012502
[TBL] [Abstract][Full Text] [Related]
17. The third conformation of p38α MAP kinase observed in phosphorylated p38α and in solution.
Akella R; Min X; Wu Q; Gardner KH; Goldsmith EJ
Structure; 2010 Dec; 18(12):1571-8. PubMed ID: 21134636
[TBL] [Abstract][Full Text] [Related]
18. Fluorescence polarization-based assays for detecting compounds binding to inactive c-Jun N-terminal kinase 3 and p38α mitogen-activated protein kinase.
Ansideri F; Lange A; El-Gokha A; Boeckler FM; Koch P
Anal Biochem; 2016 Jun; 503():28-40. PubMed ID: 26954235
[TBL] [Abstract][Full Text] [Related]
19. Implications for selectivity of 3,4-diarylquinolinones as p38alphaMAP kinase inhibitors.
Peifer C; Urich R; Schattel V; Abadleh M; Röttig M; Kohlbacher O; Laufer S
Bioorg Med Chem Lett; 2008 Feb; 18(4):1431-5. PubMed ID: 18207396
[TBL] [Abstract][Full Text] [Related]
20. TAB1 binding induced p38α conformation change: an accelerated molecular dynamics simulation study.
Zang Y; Wang H; Kang Y; Zhang J; Li X; Zhang L; Yang Z; Zhang S
Phys Chem Chem Phys; 2022 May; 24(17):10506-10513. PubMed ID: 35441632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
